Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, Ohradanova-Repic A, Weseslindtner L, Tajti G, Gebetsberger L, Kratzer B, Tomosel E, Kutschera M, Tobudic S, Pickl WF, Kundi M, Stockinger H, Novacek G, Reinisch W, Zielinski C, Wiedermann U. Wagner A, et al. Among authors: tobudic s. Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022. Front Immunol. 2022. PMID: 35634285 Free PMC article. Clinical Trial.
Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H. Lagler H, et al. Among authors: tobudic s. Vaccine. 2012 Nov 6;30(48):6864-70. doi: 10.1016/j.vaccine.2012.09.005. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989690
A Longitudinal Seroprevalence Study Evaluating Infection Control and Prevention Strategies at a Large Tertiary Care Center with Low COVID-19 Incidence.
Schubert L, Strassl R, Burgmann H, Dvorak G, Karer M, Kundi M, Kussmann M, Lagler H, Lötsch F, Milacek C, Obermueller M, Oesterreicher Z, Steininger C, Stiasny K, Thalhammer F, Traby L, Vass Z, Vossen MG, Weseslindtner L, Winkler S, Tobudic S. Schubert L, et al. Among authors: tobudic s. Int J Environ Res Public Health. 2021 Apr 15;18(8):4201. doi: 10.3390/ijerph18084201. Int J Environ Res Public Health. 2021. PMID: 33921037 Free PMC article.
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. Mrak D, et al. Among authors: tobudic s. Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20. Ann Rheum Dis. 2021. PMID: 34285048
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.
Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, Steindl A, Perkmann T, Haslacher H, Strassl R, Tobudic S, Lamm WW, Raderer M, Mitterer M, Fuereder T, Fong D, Preusser M. Mair MJ, et al. Among authors: tobudic s. JAMA Oncol. 2022 Jan 1;8(1):106-113. doi: 10.1001/jamaoncol.2021.5437. JAMA Oncol. 2022. PMID: 34591965 Free PMC article.
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, Sautner J, Radner H, Winkler F, Burgmann H, Mrak D, Aletaha D, Winkler S, Blüml S. Simader E, et al. Among authors: tobudic s. Ann Rheum Dis. 2022 Mar;81(3):416-421. doi: 10.1136/annrheumdis-2021-221347. Epub 2021 Nov 29. Ann Rheum Dis. 2022. PMID: 34844927
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Zeitlinger M, Heinz LX, Aletaha D. Bonelli M, et al. Among authors: tobudic s. Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13. Ann Rheum Dis. 2022. PMID: 35027397 Clinical Trial.
78 results